search
Back to results

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation (O2flow-COPD)

Primary Purpose

COPD Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation

Status
Recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Oxygen gas
Sponsored by
Hospital of South West Jutland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COPD Exacerbation focused on measuring COPD, Oxygen treatment, Mortality

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age 18 years or older
  • ability to give informed consent
  • previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or from their general practitioner or confirmed diagnosis by the treating physician in the emergency department (verified by use of relevant medication))
  • admitted with acute exacerbation (acute and worsened shortness of breath) of COPD
  • requiring oxygen treatment

Exclusion Criteria:

  • Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or non-invasive ventilation, within the first 30 minutes
  • Expected total length of stay in hospital < 12 hours
  • Planned transfer to another hospital within 12 hours
  • Unwilling to have repeated arterial blood gas analyses within the first 12 hours
  • Patients judged terminal by treating physician in the emergency department
  • Non-residents of the particular country
  • Expected impossible follow-up
  • Fertile women (<50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG
  • Prior participation in the study

Sites / Locations

  • Sydvestjysk SygehusRecruiting
  • Holbæk Sygehus
  • Sygehus Lillebælt, Kolding
  • Odense University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

High oxygen saturation

Low oxygen saturation

Arm Description

Peripheral oxygen saturation level >94%

Peripheral oxygen saturation level 88-92%

Outcomes

Primary Outcome Measures

30-day all-cause mortality
Data is extracted from the Danish national registries.

Secondary Outcome Measures

7-day all-cause mortality
Data is extracted from the Danish national registries.
Non-invasive ventilation
The Medical records will be reviewed for documentation on if the patient has been on non-invasive ventilation. This will be reported as proportion of patients on NIV
Intubation
The Medical records will be reviewed for documentation on if the patient has been intubated. This will be reported as proportion of patients intubated
Intensive care admission
Extracted from the hospital records.
Overall length of hospital stay
Time calculated from the hospital records
Respiratory acidosis
Measured as an arterial blood gas analysis with pH > 7.35 and hypercapnia

Full Information

First Posted
January 7, 2020
Last Updated
October 31, 2022
Sponsor
Hospital of South West Jutland
Collaborators
Holbaek Sygehus, Odense University Hospital, Sygehus Lillebaelt
search

1. Study Identification

Unique Protocol Identification Number
NCT04223050
Brief Title
Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation
Acronym
O2flow-COPD
Official Title
Will Titrated Oxygen Flow to a Peripheral Oxygen Saturation of 88-92% Compared With Oxygen Flow to a Saturation >94% Reduce Mortality in Chronic Obstructive Pulmonary Disease Patients With Acute Exacerbation? - a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 3, 2020 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital of South West Jutland
Collaborators
Holbaek Sygehus, Odense University Hospital, Sygehus Lillebaelt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Chronic obstructive pulmonary disease (COPD) is a common disorder that affects approximately 400,000 Danish citizens. About 3,000-3,500 Danes die yearly because of the disorder, and the costs associated with hospital admissions are estimated to be 535 million Danish kroner (DKK). Patients with COPD risk a worsening of their disorder, and in most cases, this will require hospitalization. One of the used treatments is providing oxygen to the patients via e.g. masks. The recommendations on oxygen treatment are currently based on a study from 2010 where 37% of the participants in this study did not receive the intended treatment, which may have had massive effects on the results. It is worrying that no other studies have shown which oxygen treatment is safest for the patients. As such, we deem it important to study how best to treat the patients. Our study is of high clinical relevance as hospitals receive patients with worsening of COPD daily. We need more, better data regarding the oxygen treatment of our patients, in order to provide our patients with the best possible care. The purpose of our study is thus to determine which oxygen treatment is best for patients with acute worsening of COPD symptoms. We will use a prospective, randomized controlled open-label trial. We will use two treatments: Treatment 1 is giving oxygen to the patient to reach a peripheral oxygen saturation of above 94%. Treatment 2 is giving oxygen to reach a peripheral oxygen saturation of between 88% and 92%. Our primary outcome is 30-day all-cause mortality, with secondary outcomes being 7-day all-cause mortality, need for non-invasive ventilation, intubation or intensive care admission, over-all length of hospital stay and respiratory acidosis. We believe that a lower oxygen saturation percentage may be superior as one study (Austin et al., 2010) showed a lower mortality rate in the group of patients that had a lower peripheral oxygen saturation. Additionally, the risk of respiratory acidosis and hypercapnia were lower. We wish to perform our study in the hospital sector as this study was performed in the prehospital sector and thus their results cannot be translated directly.
Detailed Description
Please refer to the full protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation
Keywords
COPD, Oxygen treatment, Mortality

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomization will be performed as block randomization with a 1:1 allocation using an electronic randomization system accessible via the internet (REDCap via OPEN at the University of Southern Denmark). The participants will be randomized electronically bedside by the study representatives.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
415 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High oxygen saturation
Arm Type
Active Comparator
Arm Description
Peripheral oxygen saturation level >94%
Arm Title
Low oxygen saturation
Arm Type
Active Comparator
Arm Description
Peripheral oxygen saturation level 88-92%
Intervention Type
Drug
Intervention Name(s)
Oxygen gas
Intervention Description
Administering oxygen to achieve the desired peripheral oxygen saturation
Primary Outcome Measure Information:
Title
30-day all-cause mortality
Description
Data is extracted from the Danish national registries.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
7-day all-cause mortality
Description
Data is extracted from the Danish national registries.
Time Frame
7 days
Title
Non-invasive ventilation
Description
The Medical records will be reviewed for documentation on if the patient has been on non-invasive ventilation. This will be reported as proportion of patients on NIV
Time Frame
12 hours
Title
Intubation
Description
The Medical records will be reviewed for documentation on if the patient has been intubated. This will be reported as proportion of patients intubated
Time Frame
12 hours
Title
Intensive care admission
Description
Extracted from the hospital records.
Time Frame
1 day
Title
Overall length of hospital stay
Description
Time calculated from the hospital records
Time Frame
10 days
Title
Respiratory acidosis
Description
Measured as an arterial blood gas analysis with pH > 7.35 and hypercapnia
Time Frame
12 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 18 years or older ability to give informed consent previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or from their general practitioner or confirmed diagnosis by the treating physician in the emergency department (verified by use of relevant medication)) admitted with acute exacerbation (acute and worsened shortness of breath) of COPD requiring oxygen treatment Exclusion Criteria: Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or non-invasive ventilation, within the first 30 minutes Expected total length of stay in hospital < 12 hours Planned transfer to another hospital within 12 hours Unwilling to have repeated arterial blood gas analyses within the first 12 hours Patients judged terminal by treating physician in the emergency department Non-residents of the particular country Expected impossible follow-up Fertile women (<50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG Prior participation in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mikkel Brabrand, MD PhD
Phone
+45 7918 5934
Email
mikkel.brabrand@rsyd.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Line E. Lilholm Laugesen, MScPH
Phone
+45 7918 5934
Email
Line.Emilie.Lilholm.Laugesen@rsyd.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Hallas, MD
Organizational Affiliation
Holbaek Sygehus
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sune Laugesen, MD
Organizational Affiliation
Odense University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Simon Thorgaard-Rasmussen, MD
Organizational Affiliation
Sygehus Lillebælt, Kolding
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sydvestjysk Sygehus
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mikkel Brabrand, MD PhD
Phone
+45 7918 5934
Email
mikkel.brabrand@rsyd.dk
Facility Name
Holbæk Sygehus
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Hallas, MD
Phone
59 48 38 01
Email
phaa@regionsjaelland.dk
Facility Name
Sygehus Lillebælt, Kolding
City
Kolding
ZIP/Postal Code
6000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Thorgaard-Rasmussen, MD
Email
Simon.Thorgaard-Rasmussen@rsyd.dk
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sune Laugesen, MD
Email
Sune.Laugesen@rsyd.dk

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
(Indsæt senere)

Learn more about this trial

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation

We'll reach out to this number within 24 hrs